var data={"title":"Tobramycin (systemic): Pediatric drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tobramycin (systemic): Pediatric drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/788626?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tobramycin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Tobramycin (systemic): Drug information \t&quot;</a> and <a href=\"topic.htm?path=tobramycin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tobramycin (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031119\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Ototoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Neurotoxicity, manifested as both auditory and vestibular ototoxicity, can occur. The auditory changes are irreversible, are usually bilateral, and may be partial or total. Eighth nerve impairment and nephrotoxicity may develop, primarily in patients having preexisting renal damage and in those with healthy renal function to whom aminoglycosides are administered for longer periods or in higher doses than those recommended. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching, and convulsions. The risk of aminoglycoside-induced hearing loss increases with the degree of exposure to either high peak or high trough serum concentrations. Patients who develop cochlear damage may not have symptoms during therapy to warn them of eighth-nerve toxicity, and partial or total irreversible bilateral deafness may continue to develop after the drug has been discontinued. Keep patients treated with tobramycin injection and other aminoglycosides under close clinical observation because these drugs have an inherent potential for causing ototoxicity.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Rarely, nephrotoxicity may not become apparent until the first few days after cessation of therapy. Aminoglycoside-induced nephrotoxicity usually is reversible. Keep patients treated with tobramycin injection and other aminoglycosides under close clinical observation because these drugs have an inherent potential for causing nephrotoxicity.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Monitoring:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Closely monitor renal and eighth nerve function in patients with known or suspected renal impairment and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Periodically monitor peak and trough serum concentrations of aminoglycosides during therapy to assure adequate levels and to avoid potentially toxic levels. Prolonged serum concentrations above 12 mcg/mL should be avoided. Rising trough levels (above 2 mcg/mL) may indicate tissue accumulation. Such accumulation, excessive peak concentrations, advanced age, and cumulative dose may contribute to ototoxicity and nephrotoxicity. Examine urine for decreased specific gravity and increased excretion of protein, cells, and casts. Periodically measure serum urea nitrogen (BUN), serum creatinine, and creatinine clearance. When feasible, it is recommended that serial audiograms be obtained in patients old enough to be tested, particularly high-risk patients. Evidence of impairment of renal, vestibular, or auditory function requires discontinuation of the drug or dosage adjustment.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use tobramycin injection with caution in premature and neonatal infants because of their renal immaturity and the resulting prolongation of serum half-life of the drug.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Concurrent therapy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Avoid concurrent and sequential use of other neurotoxic or nephrotoxic antibiotics, particularly other aminoglycosides (eg, amikacin, streptomycin, neomycin, kanamycin, gentamicin, paromomycin), cephaloridine, viomycin, polymyxin B, colistin, cisplatin, and vancomycin. Other factors that may increase patient risk are advanced age and dehydration.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not give aminoglycosides concurrently with potent diuretics, such as ethacrynic acid and furosemide. Some diuretics themselves cause ototoxicity, and intravenously (IV) administered diuretics enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides can cause fetal harm when administered to a pregnant woman.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031128\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>JAMP-Tobramycin;</li>\n      <li>Tobramycin For Injection;</li>\n      <li>Tobramycin For Injection, USP;</li>\n      <li>Tobramycin Injection;</li>\n      <li>Tobramycin Injection, USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503721\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Aminoglycoside</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45504018\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage should be based on actual weight unless the patient has hydrops fetalis. Dosage should be individualized based upon serum concentration monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing; susceptible infection:</b> Limited data available: Extended interval dosing strategies may vary by institution as a wide variety of dosing regimens have been studied (de Hoog 2002; DiCenzo 2003; Hagen 2009; Hansen 2003; Ohler 2000; Serane 2009). <b>Note:</b> Consider prolongation of dosing interval when coadministered with ibuprofen or indomethacin or in neonates with history of the following: Birth depression, birth hypoxia/asphyxia, or cyanotic congenital heart disease. Some dosing based on gentamicin studies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Age-directed dosing</i> (Bradley 2016): IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &lt;30 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;14 days: 5 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &ge;15 days: 5 mg/kg/dose every 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA 30 to 34 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;10 days: 4.5 mg/kg/dose every 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &ge;11 days: 5 mg/kg/dose every 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;35 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;7 days: 4 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &ge;8 days: 5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Weight-directed dosing</i> (<i>Red Book</i> [AAP 2015]): IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body weight &lt;1 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;14 days: 5 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA 15 to 28 days: 5 mg/kg/dose every 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body weight 1 to 2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;7 days: 5 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA 8 to 28 days: 5 mg/kg/dose every 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body weight &gt;2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;7 days: 4 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA 8 to 28 days: 4 to 5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Consider single-dose administration with serum concentration monitoring in patients with urine output &lt;1 mL/kg/hour or serum creatinine &gt;1.3 mg/dL rather than scheduled dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503725\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=tobramycin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Tobramycin (systemic): Drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosage should be based on an estimate of ideal body weight. In morbidly obese children, adolescents, and adults, dosage requirement may best be estimated using a dosing weight of IBW + 0.4 (TBW - IBW). Dosage should be individualized based upon serum concentration monitoring. Initial and periodic plasma drug concentrations (eg, peak and trough with conventional dosing, post dose level at a prespecified time with extended-interval dosing) should be determined, particularly in critically ill patients with serious infections or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, or major surgery). Some dosing based on gentamicin studies:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conventional dosing:</i> Infants, Children, and Adolescents: IM, IV: 6 to 7.5 mg/kg/<b>day</b> divided every 6 to 8 hours; individualize dosing based on patient-specific clinical parameters (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extended-interval dosing:</i> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-directed: Infants, Children, and Adolescents: IV: 4.5 to 7.5 mg/kg/dose every 24 hours (Contopoulos-Ioannidis 2004; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Age-directed: Based on data from 114 patients, the following has been suggested (McDade 2010):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants &ge;3 months and Children &lt;2 years: IV: 9.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 2 to &lt;8 years: IV: 8.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;8 years and Adolescents: IV: 7 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, pulmonary infection:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conventional dosing: IM, IV: 3.3 mg/kg/dose every 8 hours (Flume 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-interval dosing: IV: Initial: 10 to 12 mg/kg/dose every 24 hours (Flume 2009; Smyth 2005; Van Meter 2009); <b>Note:</b> The CF Foundation recommends extended-interval dosing as preferred over conventional dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment:</b> Children and Adolescents: IV: 3 to 6 mg/kg/<b>day</b> divided every 8 hours; use in combination with other antibiotics dependent upon organism and source of infection (ie, valve-type) (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 3 to 7.5 mg/kg/<b>day</b> divided every 8 to 24 hours (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CNS infection: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Meningitis (Tunkel 2004):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: IV: 7.5 mg/kg/<b>day</b> divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IV: 5 mg/kg/<b>day</b> divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">VP-shunt infection, ventriculitis: Limited data available: Infants, Children, and Adolescents: Intraventricular/intrathecal <b>(use a preservative-free preparation)</b>: 5 to 20 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (CAPD)</b> (Warady 2012): Limited data available: Infants, Children, and Adolescents: Intraperitoneal: Continuous: Loading dose: 8 mg per liter of dialysate; maintenance dose: 4 mg per liter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Traditional dosing: Infants and Children 2 to 24 months: IV: 5 mg/kg/day divided every 8 hours (AAP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-interval dosing: Limited data available: Based on data from 179 patients, the following age-directed dosing has been suggested (Carapetis 2001):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;5 years: IV: 7.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 5 to 10 years: IV: 6 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;10 years and Adolescents: IV: 4.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: In underweight and nonobese patients, use of total body weight (TBW) instead of ideal body weight for determining the initial mg/kg/dose is widely accepted (Nicolau 1995). Ideal body weight (IBW) also may be used to determine doses for patients who are neither underweight nor obese (Gilbert 2009). Initial and periodic plasma drug levels (eg, peak and trough with conventional dosing, post dose level at a prespecified time with extended-interval dosing) should be determined, particularly in critically-ill patients with serious infections or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, or major surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conventional: IM, IV: 1 to 2.5 mg/kg/dose every 8 to 12 hours; to ensure adequate peak concentrations early in therapy, higher initial dosage may be considered in selected patients when extracellular water is increased (edema, septic shock, postsurgical, or trauma)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Once daily: IV: 4 to 7 mg/kg/dose once daily; some clinicians recommend this approach for all patients with normal renal function; this dose is at least as efficacious with similar, if not less, toxicity than conventional dosing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment:</b> Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following adjustments have been recommended (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 2.5 mg/kg/dose every 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer every 12 to 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer every 18 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer every 48 to 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: Dialyzable (25% to 70%): 2 mg/kg/dose; redose as indicated by serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): 2 mg/kg/dose; redose as indicated by serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): 2 to 2.5 mg/kg/dose every 12 to 24 hours, monitor serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conventional dosing: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;60 mL/minute: Administer every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 40 to 60 mL/minute: Administer every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 20 to 40 mL/minute: Administer every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 20 mL/minute: Administer every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Administer every 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-dose therapy: IV: Interval may be extended (eg, every 48 hours) in patients with moderate renal impairment (CrCl 30 to 59 mL/minute) and/or adjusted based on serum concentration determinations.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days) (Heintz 2009): Dialyzable (25% to 75%; variable; dependent on filter, duration, and type of IHD); <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose of 2 to 3 mg/kg loading dose followed by:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild UTI or synergy: 1 mg/kg every 48 to 72 hours; monitor levels</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Moderate to severe UTI: 1 to 1.5 mg/kg every 48 to 72 hours; monitor levels</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Systemic gram negative rod infection: 1.5 to 2 mg/kg every 48 to 72 hours; monitor levels</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Administration via PD fluid:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Gram-positive infection (eg, synergy): 3 to 4 mg/L (3 to 4 mcg/mL) of PD fluid</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Gram-negative infection: 4 to 8 mg/L (4 to 8 mcg/mL) of PD fluid</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Administration via IV, IM route during PD: Dose as for CrCl &lt;10 mL/minute and follow serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as target drug concentrations (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVH/CVVHD/CVVHDF: IV: Loading dose of 2 to 3 mg/kg followed by:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild UTI or synergy: IV: 1 mg/kg every 24 to 36 hours; monitor levels</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Moderate to severe UTI: IV: 1 to 1.5 mg/kg every 24 to 36 hours; monitor levels</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Systemic gram-negative infection: IV: 1.5 to 2.5 mg/kg every 24 to 48 hours; monitor levels</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> No dosage adjustment necessary; does not undergo hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031190\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (2 mL); 80 mg/2 mL (2 mL); 1.2 g/30 mL (30 mL); 2 g/50 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 80 mg (100 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1.2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1.2 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031130\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503727\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer undiluted by deep IM route if possible. Slower absorption and lower peak concentrations, probably due to poor circulation in the atrophic muscle, may occur following IM injection in paralyzed patients, suggest IV route.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer by slow intermittent infusion over 30 to 60 minutes (administer higher doses over 60 minutes) or by direct injection over 15 minutes</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides in vitro. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy in vivo, particularly in the setting of profound renal impairment; however, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031148\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Stable at room temperature both as the clear, colorless solution and as the dry powder. Reconstituted solutions remain stable for 24 hours at room temperature and 96 hours when refrigerated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503722\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Treatment of documented or suspected infections caused by susceptible gram-negative bacilli, including <i>Pseudomonas aeruginosa</i>; nonpseudomonal enteric bacillus infection which is more susceptible to tobramycin than gentamicin based on microbiology testing; susceptible organisms in lower respiratory tract infections (FDA approved in adults); serious central nervous system infection caused by susceptible organisms (FDA approved in adults); septicemia (FDA approved in all ages); intra-abdominal, skin, bone, soft tissue, and urinary tract infections (FDA approved in adults); has also been used for empiric therapy in cystic fibrosis and immunocompromised patients  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031120\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tobramycin may be confused with Trobicin, vancomycin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nebcin [Multiple international markets] may be confused with Naprosyn brand name for naproxen [US, Canada, and multiple international markets]; Nubain brand name for nalbuphine [Multiple international markets]</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031200\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Confusion, disorientation, dizziness, headache, lethargy, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Exfoliative dermatitis, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Decreased serum calcium, decreased serum magnesium, decreased serum potassium, decreased serum sodium, increased lactate dehydrogenase, increased nonprotein nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Casts in urine, oliguria, proteinuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, eosinophilia, granulocytopenia, leukocytosis, leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum ALT, increased serum AST, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Auditory ototoxicity, hearing loss, tinnitus, vestibular ototoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased blood urea nitrogen, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Anaphylaxis, <i>clostridium difficile</i> associated diarrhea, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031143\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to tobramycin, other aminoglycosides, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031144\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxicity:<b> [US Boxed Warning]: May cause nephrotoxicity;</b> usual risk factors include pre-existing renal impairment, concomitant nephrotoxic medications, advanced age, and dehydration. Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular blockade and respiratory paralysis: May cause neuromuscular blockade, respiratory failure, and prolonged respiratory paralysis, especially when given soon after anesthesia or muscle relaxants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: <b>[US Boxed Warning]: May cause neurotoxicity;</b> usual risk factors include pre-existing renal impairment, concomitant neuro-/nephrotoxic medications, advanced age, and dehydration. Ototoxicity is proportional to the amount of drug given and the duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage. Tinnitus and/or hearing loss have also been reported. Discontinue treatment if signs of ototoxicity occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hearing impairment: Use with caution in patients with pre-existing vertigo, tinnitus, or hearing loss.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypocalcemia: Use with caution in patients with hypocalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis and Parkinson disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with pre-existing renal insufficiency; dosage modification required during systemic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pregnancy: <b>[US Boxed Warnings]: Aminoglycosides may cause fetal harm if administered to a pregnant woman. </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfite: Solution for injection may contain sodium metabisulfate; use caution in patients with sulfite allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Long-term use: Systemic therapy is not intended for long-term therapy due to toxic hazards associated with extended administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503999\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use with caution in premature infants and neonates; immature renal function may increase risk of accumulation and related toxicity. Use with caution in pediatric patients on extracorporeal membrane oxygenation (ECMO); pharmacokinetics of aminoglycosides may be altered; dosage adjustment and close monitoring necessary. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031205\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031202\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=105135&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arbekacin: May enhance the nephrotoxic effect of Aminoglycosides. Arbekacin may enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ataluren: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephradine: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distigmine: Aminoglycosides may diminish the therapeutic effect of Distigmine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mannitol (Systemic): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Aminoglycosides may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Aminoglycosides may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.<b> Exceptions: </b>Amoxicillin; Ampicillin; Bacampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Benzathine; Penicillin V Potassium.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031138\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031139\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Aminoglycosides may cause fetal harm if administered to a pregnant woman.</b> Tobramycin crosses the placenta. There are several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy. Although serious side effects to the fetus/infant have not been reported following maternal use of all aminoglycosides, a potential for harm exists. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of tobramycin may be altered (Bourget 1991). Tobramycin injection may be used for the management of cystic fibrosis in pregnant patients with <i>Pseudomonas aeruginosa</i> (inhalation is preferred unless risk of infection is great) (Edenborough 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503728\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Urinalysis, urine output, BUN, serum creatinine, peak and trough serum tobramycin concentrations; <b>Note:</b> Do not use fingerstick for obtaining blood sample in patients concurrently receiving inhaled tobramycin as it may result in falsely elevated drug concentrations); be alert to ototoxicity, audiograms </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">With conventional dosing, typically obtain serum concentration after the third dose; exceptions for earlier monitoring may include neonates, patients with rapidly changing renal function, or patients receiving extended-interval dosing. Not all pediatric patients who receive aminoglycosides require monitoring of serum aminoglycoside concentrations. Indications for use of aminoglycoside serum concentration monitoring include: </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">Treatment course &gt;5 days </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">Patients with decreased or changing renal function </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">Patients with a poor therapeutic response </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">Neonates and Infants &lt;3 months of age </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">Atypical body constituency (obesity, expanded extracellular fluid volume) </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">Clinical need for higher doses or shorter intervals (cystic fibrosis, burns, endocarditis, meningitis, relatively resistant organism) </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">Patients on hemodialysis or chronic ambulatory peritoneal dialysis </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">Signs of nephrotoxicity or ototoxicity </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">Concomitant use of other nephrotoxic agents </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503729\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Traditional dosing: Timing of serum samples: Draw peak 30 minutes after 30-minute infusion has been completed or 1 hour following IM injection or beginning of infusion; draw trough immediately before next dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Therapeutic concentrations: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Serious infections: 6 to 8 mcg/mL (12 to 17 micromole/L) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Life-threatening infections: 8 to 10 mcg/mL (17 to 21 micromole/L) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Urinary tract infections: 4 to 6 mcg/mL </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Synergy against gram-positive organisms: 3 to 5 mcg/mL </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trough:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Serious infections: 0.5 to 1 mcg/mL </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Life-threatening infections: 1 to 2 mcg/mL </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">The American Thoracic Society (ATS) recommends trough levels of &lt;1 mcg/mL for adult patients with hospital-acquired pneumonia. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Timing of serum samples: Draw peak 30 minutes after completion of 30-minute infusion or at 1 hour following initiation of infusion or IM injection; draw trough within 30 minutes prior to next dose; aminoglycoside levels measured from blood taken from Silastic central catheters can sometimes give falsely elevated readings </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Extended-interval: <b>Note:</b> Pediatric therapeutic monitoring protocols have not been standardized; peak values are 2 to 3 times greater with extended-interval dosing regimens compared to traditional dosing </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Noncystic fibrosis patients: Consider monitoring tobramycin serum concentration 18 to 20 hours after the start of the infusion to ensure the drug-free interval does not exceed typical postantibiotic effect (PAE) duration. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cystic fibrosis patients: Clinically two methods are utilized. Peak: 25 to 35 mcg/mL (some centers use 20 to 30 mcg/mL); 18- to 20-hour value: Detectable but &lt;1 mcg/mL; trough: Nondetectable </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Method A: Obtain two serum concentrations at least 1 half-life apart after distribution is complete (eg, obtain a serum concentration 2 hours and 10 hours after the start of the infusion), calculate elimination rate and extrapolate a C<sub>max</sub> and C<sub>min</sub></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Method B: Obtain a peak serum concentration 60 minutes after a 60-minute infusion and a serum concentration 18 to 20 hours after the start of the infusion to ensure the drug-free interval does not exceed typical postantibiotic effect (PAE) duration (4 to 6 hours) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031152\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with bacterial protein synthesis by binding to 30S ribosomal subunit, resulting in a defective bacterial cell membrane</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031155\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Poorly absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Rapid and complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: DIstributes to extracellular fluid, including serum, abscesses, ascitic, pericardial, pleural, synovial, lymphatic, and peritoneal fluids; poor penetration into CSF, eye, bone, prostate; V<sub>d</sub>: Higher in neonates than older pediatric and adult patients; also increased in patients with edema, ascites, fluid overload; decreased in patients with dehydration; Systemic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: 0.45 &plusmn; 0.1 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: 0.4 &plusmn; 0.1 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 0.35 &plusmn; 0.15 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents: 0.3 &plusmn; 0.1 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 0.2 to 0.3 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &lt;30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: &le;1,200 g: 11 hours; &gt;1,200 g: 2 to 9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: 4 &plusmn; 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 2 &plusmn; 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents: 1.5 &plusmn; 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: IV: 2 to 3 hours; directly dependent upon glomerular filtration rate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults with impaired renal function: 5 to 70 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: 30 to 60 minutes; IV: ~30 minutes; <b>Note:</b> Distribution may be prolonged after larger doses. One study reported a 1.7-hour distribution period after a 60-minute, high-dose aminoglycoside infusion (Demczar 1997). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Normal renal function: Urine (~90% to 95%) within 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031194\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Tobramycin Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.2 g/30 mL (30 mL): $27.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 gm/50 mL (50 mL): $49.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (2 mL): $4.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/2 mL (2 mL): $2.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Tobramycin Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.2 g (1): $93.24</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45649945\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bactob (IN);</li>\n      <li>Brulamycin (HU);</li>\n      <li>Intolacin (VN);</li>\n      <li>Jiu Tai (CN);</li>\n      <li>Nebcin (AE, EG, PK, VN);</li>\n      <li>Nebcina (DK, NO);</li>\n      <li>Nebcine (FR);</li>\n      <li>Obracin (BE, CH);</li>\n      <li>Rui Nuo Sai (CN);</li>\n      <li>Tobra (KR);</li>\n      <li>Tobra-Day (AU, NZ);</li>\n      <li>Tobra-gobens (ES);</li>\n      <li>Tobracin (EG, JO);</li>\n      <li>Tobrasik (AT);</li>\n      <li>Tobrin (EG, QA);</li>\n      <li>Tocin (PK);</li>\n      <li>Tofib (AR);</li>\n      <li>Tomycin (FI)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics</i>. 2011;128(3):595-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/21873693/pubmed\" target=\"_blank\" id=\"21873693\">21873693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. <i>J Antimicrob Chemother</i>. 2002;50(4):553-559.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12356801/pubmed\" target=\"_blank\" id=\"12356801\">12356801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association.  <i>Circulation</i>. 2015;132(15):1487-1515<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bartel K, Habash T, Lugauer S, et al, &quot;Optimal Tobramycin Dosage in Patients With Cystic Fibrosis &minus; Evidence for Predictability Based on Previous Drug Monitoring,&quot; <i>Infection</i>, 1999, 27(4-5):268-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/10885841/pubmed\" target=\"_blank\" id=\"10885841\">10885841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bourget P, Fernandez H, Delouis C, et al, &quot;Pharmacokinetics of Tobramycin in Pregnant Women. Safety and Efficacy of a Once-Daily Dose Regimen,&quot; <i>J Clin Pharm Ther</i>, 1991, 16(3):167-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/1869596/pubmed\" target=\"_blank\" id=\"1869596\">1869596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 22nd ed. American Academy of Pediatrics; 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/1869596/pubmed\" target=\"_blank\" id=\"1869596\">1869596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carapetis JR, Jaquiery AL, Buttery JP, et al, &quot;Randomized, Controlled Trial Comparing Once Daily and Three Times Daily Gentamicin in Children With Urinary Tract Infections,&quot; <i>Pediatr Infect Dis J</i>, 2001, 20(3):240-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/11303823/pubmed\" target=\"_blank\" id=\"11303823\">11303823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12431134 /pubmed\" target=\"_blank\" id=\"12431134 \">12431134 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, et al, &quot;Extended-Interval Aminoglycoside Administration for Children: A Meta-Analysis,&quot; <i>Pediatrics</i>, 2004, 114(1):e111-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/15231982/pubmed\" target=\"_blank\" id=\"15231982\">15231982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Hoog M, Mouton JW, Schoemaker RC, et al, &quot;Extended-Interval Dosing of Tobramycin in Neonates: Implications for Therapeutic Drug Monitoring,&quot; <i>Clin Pharmacol Ther</i>, 2002, 71(5):349-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12011820/pubmed\" target=\"_blank\" id=\"12011820\">12011820</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Demczar DJ, Nafziger AN, and Bertino JS Jr, &quot;Pharmacokinetics of Gentamicin at Traditional Versus High Doses: Implications for Once-Daily Aminoglycoside Dosing,&quot; <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1115-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/9145878/pubmed\" target=\"_blank\" id=\"9145878\">9145878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DiCenzo R, Forrest A, Slish JC, et al, &quot;A Gentamicin Pharmacokinetic Population Model and Once-Daily Dosing Algorithm for Neonates,&quot; <i>Pharmacotherapy</i>, 2003, 23(5):585-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12741432/pubmed\" target=\"_blank\" id=\"12741432\">12741432</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edenborough FP, Borgo G, Knoop C, et al. Guidelines for the management of pregnancy in women with cystic fibrosis. <i>J Cyst Fibros</i>. 2008;7(Suppl 1):S2-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/18024241 /pubmed\" target=\"_blank\" id=\"18024241 \">18024241 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Festini F, Ciuti R, Taccetti G, et al, &quot;Breast-Feeding in a Woman With Cystic Fibrosis Undergoing Antibiotic Intravenous Treatment,&quot; <i>J Matern Fetal Neonatal Med</i>, 2006, 19(6):375-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/16801316/pubmed\" target=\"_blank\" id=\"16801316\">16801316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flume PA, Mogayzel PJ Jr, Robinson KA, et al, &quot;Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations,&quot; <i>Am J Respir Crit Care Med</i>, 2009, 180(9):802-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/19729669/pubmed\" target=\"_blank\" id=\"19729669\">19729669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert DN, &quot;Once-Daily Aminoglycoside Therapy,&quot; <i>Antimicrob Agents Chemother</i>, 1991, 35(3):399-405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/2039189 /pubmed\" target=\"_blank\" id=\"2039189 \">2039189 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Green TP, Mirkin BL, Peterson PK, et al, &quot;Tobramycin Serum Level Monitoring in Young Patients With Normal Renal Function,&quot; <i>Clin Pharmacokinet</i>, 1984, 9(5):457-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/6499344/pubmed\" target=\"_blank\" id=\"6499344\">6499344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hagen I and &Oslash;ymar K, &quot;Pharmacological Differences Between Once Daily and Twice Daily Gentamicin Dosage in Newborns With Suspected Sepsis,&quot; <i>Pharm World Sci</i>, 2009, 31(1):18-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/18982422/pubmed\" target=\"_blank\" id=\"18982422\">18982422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hansen A, Forbes P, Arnold A, et al, &quot;Once-Daily Gentamicin Dosing for the Preterm and Term Newborn: Proposal for a Simple Regimen That Achieves Target Levels,&quot; <i>J Perinatol</i>, 2003, 23(8):635-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/14647159/pubmed\" target=\"_blank\" id=\"14647159\">14647159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, and Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knoderer CA, Everett JA, and Buss WF, &quot;Clinical Issues Surrounding Once-Daily Aminoglycoside Dosing in Children,&quot; <i>Pharmacotherapy</i>, 2003, 23(1):44-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12523459/pubmed\" target=\"_blank\" id=\"12523459\">12523459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kraus DM, Pai MP, and Rodvold KA, &quot;Efficacy and Tolerability of Extended-Interval Aminoglycoside Administration in Pediatric Patients,&quot; <i>Paediatr Drugs</i>, 2002, 4(7):469-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12083974/pubmed\" target=\"_blank\" id=\"12083974\">12083974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandell GL, Bennett JE, Dolin R, eds, <i>Aminoglycosides</i>.  <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases</i>. 7th ed. Chapter 26.  Philadelphia, PA: Churchill Linvingstone Elsevier; 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Massie J and Cranswick N, &quot;Pharmacokinetic Profile of Once Daily Intravenous Tobramycin in Children With Cystic Fibrosis,&quot; <i>J Paediatr Child Health</i>, 2006, 42(10):601-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/16972966/pubmed\" target=\"_blank\" id=\"16972966\">16972966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDade EJ, Wagner JL, Moffett BS, et al, &quot;Once-Daily Gentamicin Dosing in Pediatric Patients Without Cystic Fibrosis,&quot; <i>Pharmacotherapy</i>, 2010, 30(3):248-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/20180608/pubmed\" target=\"_blank\" id=\"20180608\">20180608</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. <i>Am J Respir Crit Care Med</i>. 2013;187(7):680-689.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/23540878/pubmed\" target=\"_blank\" id=\"23540878\">23540878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mouton JW, Jacobs N, Tiddens H, et al, &quot;Pharmacodynamics of Tobramycin in Patients With Cystic Fibrosis,&quot; <i>Diagn Microbiol Infect Dis</i>, 2005, 52(2):123-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/15964500/pubmed\" target=\"_blank\" id=\"15964500\">15964500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahata MC, Powell DA, Durrell DE, et al, &quot;Effect of Gestational Age and Birth Weight on Tobramycin Kinetics in Newborn Infants,&quot; <i>J Antimicrob Chemother</i>, 1984, 14(1):59-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/6480541/pubmed\" target=\"_blank\" id=\"6480541\">6480541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. <i>Antimicrob Agents Chemother</i>. 1995;39(3):650-655.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/7793867/pubmed\" target=\"_blank\" id=\"7793867\">7793867</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohler KH, Menke JA, and Fuller L, &quot;Use of Higher Dose Extended Interval Aminoglycosides in a Neonatal Intensive Care Unit,&quot; <i>Am J Perinatol</i>, 2000, 17(6):285-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/11144309/pubmed\" target=\"_blank\" id=\"11144309\">11144309</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ratjen F, Munck A, Kho P, Angyalosi G; ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. <i>Thorax</i>. 2010;65(4):286-291.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/19996339 /pubmed\" target=\"_blank\" id=\"19996339 \">19996339 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Redmann S, Wainwright C, Stacey S, et al, &quot;Misleading High Tobramycin Plasma Concentrations Can Be Caused by Skin Contamination of Fingerprick Blood Following Inhalation of Nebulized Tobramycin (TOBI): A Short Report,&quot; <i>Ther Drug Monit</i>, 2005, 27(2):205-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/15795653/pubmed\" target=\"_blank\" id=\"15795653\">15795653</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Serane TV, Zengeya S, Penford G, et al, &quot;Once Daily Dose Gentamicin in Neonates - Is Our Dosing Correct?&quot; <i>Acta Paediatr</i>, 2009, 98(7):1100-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/19397541/pubmed\" target=\"_blank\" id=\"19397541\">19397541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smyth A, Tan KH, Hyman-Taylor P, et al, &quot;Once Versus Three-Times Daily Regimens of Tobramycin Treatment for Pulmonary Exacerbations of Cystic Fibrosis &minus; The TOPIC Study: A Randomised Controlled Trial,&quot; <i>Lancet</i>, 2005, 365(9459):573-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/15708100/pubmed\" target=\"_blank\" id=\"15708100\">15708100</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>,  2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobramycin injection, solution) [prescribing information]. Lake Forest,IL: Akorn Inc; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uwaydah M, Bibi S, and Salman S, &quot;Therapeutic Efficacy of Tobramycin - A Clinical and Laboratory Evaluation,&quot; <i>J Antimicrob Chemother</i>, 1975, 1(4):429-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/1107297/pubmed\" target=\"_blank\" id=\"1107297\">1107297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Meter DJ, Corriveau M, Ahern JW, et al, &quot;A Survey of Once-Daily Dosage Tobramycin Therapy in Patients With Cystic Fibrosis,&quot; <i>Pediatr Pulmonol</i>, 2009, 44(4):325-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/19330772/pubmed\" target=\"_blank\" id=\"19330772\">19330772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al, &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, (32 Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 105135 Version 46.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F45031119\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F45031128\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F45503721\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F45504018\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F45503725\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45031190\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F45031130\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45503727\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F45031148\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45503722\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45031120\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45031200\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45031143\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45031144\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F45503999\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45031205\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45031202\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F45031138\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45031139\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45503728\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F45503729\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45031152\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F45031155\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F45031194\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45649945\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/105135|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tobramycin-systemic-drug-information\" class=\"drug drug_general\">Tobramycin (systemic): Drug information \t</a></li><li><a href=\"topic.htm?path=tobramycin-systemic-patient-drug-information\" class=\"drug drug_patient\">Tobramycin (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}